Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26508312.
- Also identified by DOI 10.1016/j.eururo.2015.10.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.
Medical subject headings
- Anilides
- Antibodies, Monoclonal
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Practice Guidelines as Topic
- Pyridines